Positive Trigger
now
Independent Data Monitoring Committee (IDMC) issues an unblinded review passing 'Galinpepimut-S' in AML Phase 3 trials, recommending trial continuation without modifications.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |